RNA-based therapeutic technologies represent a rapidly expanding class of therapeutic opportunities with the power to modulate cellular biology in ways never before possible. With RNA-targeted therapeutics, inhibitors of previously undruggable proteins, gene expression modulators, and even therapeutic proteins can be rationally designed based on sequence information alone, something that is not possible with other therapeutic modalities. The most advanced RNA therapeutic modalities are antisense oligonucleotides (ASOs) and small interfering RNAs. Particularly with ASOs, recent clinical data have demonstrated proof of mechanism and clinical benefit with these approaches across several nononcology disease areas by multiple routes of administration. In cancer, next-generation ASOs have recently demonstrated single-agent activity in patients with highly refractory cancers. Here we discuss advances in RNA therapeutics for the treatment of cancer and the challenges that remain to solidify these as mainstay therapeutic modalities to bridge the pharmacogenomic divide that remains in cancer drug discovery.
Our understanding of the molecular events controlling tumor growth, survival, immune escape, and metastasis has dramatically increased over the last decades. Large-scale programs such as The Cancer Genome Atlas project have identified previously unknown highfrequency mutations in various cancers and identified many of the genetic events most likely to be important "drivers" of cancer as well as those that may be simply "passenger" mutations. [1] [2] [3] In addition, the widespread availability of functional genomic tools, such as antisense technology, small interfering (si)RNA, short hairpin RNA vectors, and more recently CRISPR systems, has allowed the cancer research community to carefully evaluate the role of candidate genes and pathways and define their contributions to various aspects of tumorigenesis. Importantly, from these efforts, novel ideas about the fundamentals of the cancer process itself have emerged. Included among these are the important supporting roles of nontumor cells in the tumor microenvironment, the concept of cancer stem cells, epithelial-to-mesenchymal transitions, the various mechanisms that tumors employ to ensure immune evasion, the principle of oncogene addiction, and the increasingly interesting contribution of noncoding RNAs and microRNAs, to name only a few. [4] [5] [6] [7] These insights, when coupled to novel technologies that are sufficiently specific to selectively affect these novel targets, provide great hope that cancer treatment will finally move away from untargeted cytotoxic therapy to selective molecular targeted therapies and that these will lead to novel lifesaving therapies.
However, this hope has not yet been realized. This is due in part to the difficulty, cost, and time involved in identifying potent, selective drugs that can modulate therapeutically relevant target proteins. Many of the proteins that play critical functions in the cancer process are members of protein classes that are inherently difficult to design inhibitors toward, a feature that is often referred to as a protein being "difficult to drug." The result is that many of the most interesting cancer targets and pathways remain undrugged.
Therapeutic nucleic acid approaches such as antisense technology, siRNA, and therapeutic mRNA hold enormous potential as cancer therapeutics. In contrast to other therapeutic approaches, the druggable universe is not limited with these modalities because therapeutics can be rationally designed based on well-defined principles: mRNA inhibitors or modulators can be designed based on Watson-Crick hybridization rules, and RNAbased therapeutic proteins can be designed based on the protein code. In addition, these approaches afford a gene-selective specificity that cannot be achieved by other modalities, especially when we are targeting protein classes that often have multiple highly homologous family members. Thus, with RNA therapeutics, previously intractable targets can be selectively drugged. Examples of such previously undruggable target classes include not only protein-coding mRNAs but also premRNAs and non-protein-coding RNAs such as long noncoding RNAs and microRNAs (miRNA). Noncoding RNAs are a particularly interesting class of molecules, and since their discovery, studies over the last decade have clearly demonstrated that noncoding RNAs are important contributors to gene expression regulation during development and in many disease states including cancer. 8, 9 Clearly, as these RNAs do not code for proteins, they can only be targeted by approaches such as antisense.
Here we review the status of RNA therapeutic strategies for the treatment of cancer as well as the challenges they face along the path to becoming a mainstay of modern cancer treatment.
RNA Therapeutics: An Expanding Class of Therapeutic Agents With Diverse Mechanisms of Action

RNA Therapeutics Based on Antisense Principles
The concept of antisense oligonucleotides was first described in 1978, when Stephenson and Zamecnik reported that a chemically modified oligonucleotide, designed to bind to its complementary sequence in a Rous sarcoma virus transcript, inhibited gene expression and viral replication. 10 The concept suggested that the synthetic single-stranded oligonucleotides could selectively bind to the target RNA through WatsonCrick hybridization and inhibit RNA function. At the time, however, there was little understanding as to how these oligonucleotides (which later came to be called antisense oligonucleotides [ASOs] ) elicited their cellular effects on binding to target RNAs. Since those initial findings, a tremendous amount of work has been done to understand the cellular fate of RNA molecules when targeted by ASOs. These efforts have now resulted in our ability to rationally design ASOs that have effective drug-like properties yet can still potently control the fate of RNA molecules in unanticipated and diverse ways, through multiple postbinding mechanisms including the modulation of RNA splicing, the inhibition of mRNA translation into protein, the disruption of necessary RNA structures regulating RNA stability, inhibition of 3-polyadenylation, and, 1 of the most commonly employed mechanisms, the catalytic degradation of target RNA molecules by the recruitment of RNase H1. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Moreover, it is important to note that RNA interference (RNAi)-mediated silencing of gene expression is itself, in fact, based on the mechanism of antisense hybridization to target RNAs, with the distinction that a double-stranded RNA:RNA duplex is for the most part required to load the RNAi molecule into the RNA-induced silencing complex (RISC; see the following section on argonaute-2 (AGO2)-mediated silencing).
Most of these mechanisms mediate the reduction of a given target RNA; however, importantly, several novel antisense mechanisms that lead to the upregulation of gene expression have now been demonstrated, including the targeting of endogenous antisense transcripts themselves, the targeting of upstream open reading frames on mRNAs, and the modulation of mRNA nonsense-mediated decay pathways and by the targeted disruption of structured regions in RNA molecules (see Table 1 for a summary of antisense mechanisms). [21] [22] [23] [24] [25] As a result, these various antisense mechanisms represent the most direct means known to translate genomic sequence information into selective therapeutics agents capable of modulating gene expression of previously undruggable proteins in diverse ways to treat disease (Table 1) .
Due to the unfavorable physicochemical properties of naturally occurring nucleic acids, the potential of RNA therapeutics as a class has relied heavily on strategies to overcome several biological barriers to improve the absorption, distribution, metabolism, and elimination (ADME) properties of these agents. For single-stranded RNA therapeutics, medicinal chemistry advances in conjunction with mechanistic studies of over the past 20 years have resulted in substantial improvements in both the potency and the biological stability of ASO drugs (Figure 1) . One of the first barriers encountered following the administration of a nucleic acid therapeutic molecule is presented by the nuclease activity in plasma and tissues, which rapidly degrades the naturally occurring phosphodiester linkage of nucleic acids. There have been several recent reviews describing in detail the chemical approaches to overcoming the nuclease sensitivity of single-stranded RNA therapeutic, and double-stranded siRNAs. 26, 27 The substitution of sulfur for oxygen to generate phosphorothiate (PS) internucleotide linkages is the most common and most effective means to date to stabilize nucleic acid molecules against nucleasemediated degradation. 28 In addition to increased nuclease resistance, PS linkages also greatly increase the binding of nucleic acids, particularly single-stranded nucleic acids (ASOs, miRNAs) to serum proteins (principally albumin) leading to prolonged circulation in plasma, decreased clearance by the kidney enhanced cellular uptake and importantly, can significantly influence intracellular protein binding and subcellular distribution. [29] [30] [31] Single-stranded oligonucleotides are amphipathic as the nucleobases are lipid soluble whereas the phosphate is water soluble. [32] [33] [34] The substitution of PS for PO increases the hydrophobicity of the phosphate and thus increases interactions with proteins. Optimization of ASOs to minimize the interaction with proteins that induce inflammatory reactions and other adverse effects has greatly enhanced the performance of PS-modified oligonucleotides. An example of this type of modification is the 2ʹ-methoxyethyl (MOE) modification. 29 Importantly, MOE chemistry, when incorporated into novel Gapmer ASO designs in which MOE modifications are included in several of the 5ʹ and 3ʹ nucleotides (or wings of the molecule) and a central deoxyribose (DNA) portion (or GAP) resulted in molecules with excellent nuclease stability, increased affinity for target RNAs and produced a good balance between binding to plasma proteins, thus decreasing renal clearance as well as minimizing interactions with proteins that would result in adverse effects. 28, 35 The next challenge for these agents, then, is their uptake into cells and delivery to subcellular compartments where the molecular mechanisms of action are invoked, which are principally the nucleus for ASO-and miRNA-based therapeutics and the cytoplasm of cells for siRNA inhibitor. The single-stranded ASOs and miRNA therapeutics can be formulated in simple saline solutions, delivered systemically, and are taken up by the cells of various tissues through endocytotic and other mechanisms that ultimately result in the liberation of intact drug from late endosomal structures and nuclear penetration. 29, 36 The precise mechanisms and molecular events resulting in ASO endocytotic uptake are only partially understood and are an intense area of research. 36 Nonetheless, the nucleic acid-based therapeutics has been extensively characterized in numerous biological systems, and it is now understood that, on systemic delivery, unformulated ASOs rapidly distribute to most tissues, and once taken up by cells, these stabilized molecules have prolonged tissue halflives of up to 2 weeks in rodents and in man. 29 The improvement in potency and ADME properties for second-generation ASOs in vivo over the firstgeneration chemistry has been shown to be as much as 10-fold, and, fortuitously, MOE Gapmers also benefit from a significantly reduced proinflammatory capacity, resulting in improved safety properties and a significantly increased therapeutic window (see Figure 2) . [37] [38] [39] Although robust clinical efficacy has been achieved for several next-generation ASO and miRNA targeted therapeutics, the ADME properties are still challenges for these agents, and continued efforts to improve on the stability, potency, and cellular delivery have recently led to notable advances. The discovery and development of N-acetyl galactosamine (GalNAc)-conjugated ASOs and RNA, siRNA, have enabled the preferential delivery of these agents to hepatocytes by virtue of the affinity of GalNAc for the hepatocyte-specific asialoglycoprotein receptors. [40] [41] [42] [43] GalNAc conjugation of siRNAs has enabled moving away from complex lipid-nanoparticle delivery modalities, and GalNAcconjugated ASOs have increased in vivo potency of approximately 32-fold in the clinic compared to unconjugated parent ASOs. 44 The second major recent advance is the discovery of a next-generation class of RNAse H1 active ASOs that employ 2ʹ-4ʹ constrained ethyl (cEt). 45, 46 These next-generation cEt ASOs exhibit enhanced in vitro and in vivo potency compared to earlier ASO molecules and have tremendous potential to target numerous extrahepatic tissues, including tumors. In addition to the advances in chemistry and ASO designs, advances in screening and insights into sequence motifs associated with unwanted effects have further enhanced next-generation ASO drugs.
Chemical modifications to improve the ADME properties of siRNA molecules have also been extensively described elsewhere. 26, 27 One of the principal issues with these double-stranded nucleic acid molecules, S47 in addition to being more than double the molecular weight of a single-stranded ASO and relatively rigid molecules, is that because of the base pairing between strands they present 2 hydrophilic faces to the biological surroundings and thus exhibit limited binding to proteins and are rapidly cleared by the glomerulus of the kidney. 29 The low protein binding of siRNAs also poses problems for cellular uptake, and as a result of these formidable challenges, efforts to deliver siRNA therapeutically have for the most part necessitated the complexation of siRNA molecules into cationic lipid or other lipid nanoparticles. 47 Unfortunately, these delivery approaches result in limited distribution primarily to the liver and are associated with such intense proinflammatory reactions that prophylactic doses of steroids, histamine antagonists, and NSAIDS are required prior to each administration, and despite these pretreatments, serious infusion reactions are reported in 20% or more of treated patients. [48] [49] [50] [51] [52] [53] [54] However, as mentioned briefly above, a more effective solution to the in vivo delivery of siRNA molecules (at least for the delivery of siRNA to hepatocytes) has been has been the conjugation of double-stranded siRNA molecules (and ASOs) to GalNAc moieties resulting in the active uptake of these conjugates into hepatocytes via Asialoglycoprotein receptors. 43 However, to achieve effective stability and distribution of GalNAcconjugated siRNAs, substantial additional chemical modifications must be incorporated, and thus, most GalNAc-conjugated siRNAs in development contain 10 to 14 PS moieties, 11 to 14 2ʹ-methoxy and 10 to 14 2ʹ-fluoro (2ʹ-F)-modified nucleosides. 55 The modifications employed in RNA therapeutic molecules can have important consequences both in the intact siRNA molecule and on metabolism. For example, 2ʹ-F nucleosides have been shown to be substrates for the salvage nucleoside pathway, becoming incorporated into DNA and RNA. 56 In some cases this has led to severe liver toxicity such as was observed with the 2ʹ-F nucleoside fialuridine. 57 Additionally, intact 2ʹ-F oligonucleotides have been shown to cause the rapid degradation of paraspeckle proteins inducing cellular toxicity. 58 Recently, treatment with revusiran, an siRNA-containing 14 2ʹ-F, 12 PS, and 14 2ʹ-methoxy nucleosides was associated with liver toxicity, lactic acidosis, and an increased risk of death in a trial in patients with transthyretin (TTR) amyloidosis. 59 In addition to the ability of RNA therapeutic approaches to inhibit targets that are not treatable by other therapeutic modalities targeted to proteins, such as small molecules and antibodies, it is important to emphasize that because the chemical properties of nucleic acids drugs do not change significantly from one drug target to another, as it is merely the sequence of the nucleotides that changes, several important features of the drugs are class properties and thus predictable. For example, physicochemical properties such as solubility, stability, and large-scale synthetic routes are shared from one drug to another. In addition, properties that are often significant risks for small-molecule therapeutics such as pharmacokinetic and ADME properties are predictable for RNA therapeutics. Moreover, the increased understanding of the clinical pharmacology of RNA therapeutic molecules has resulted in abbreviated clinical pharmacology and regulatory studies. For example, as nucleic acid-based drugs are not metabolized by cytochrome P450 enzymes (CYPs) and do not themselves inhibit CYPs, drug-drug interaction studies are not generally required, and similarly, as these agents have not been shown to interact with the cardiac hERG channels, QTc studies are not mandatory. [60] [61] [62] Taken together, the ability to inhibit previously intractable therapeutic targets and key efficiencies make RNA therapeutics an exciting drug discovery platform with enormous potential to positively impact several human diseases including cancer.
RNase H1-Active ASOs Although many of the diverse antisense mechanisms of action are of interest for therapeutics, the selective targeted degradation of specific RNAs with RNase H1-active ASOs has been the most studied, and numerous RNase H-active ASOs have now advanced into human testing across several therapeutic areas.
RNase H1-active ASOs are single-stranded DNAlike oligonucleotides that produce a DNA/RNA duplex when bound to their complementary site on a target RNA molecule, creating a substrate for the ubiquitous enzyme RNase H1 and leading to the selective cleavage of the targeted RNA molecule. Importantly, the removal of the resulting RNA fragments is processed by normal endogenous cellular mechanisms, and the products are then eliminated. 63 After cleavage, the ASO is liberated to interact with another cellular target RNA molecule, ultimately resulting in the selective cellular depletion of the target RNA species and the subsequent depletion of its corresponding protein product. 64 In a detailed set of experiments the kinetics of the major steps in the molecular mechanism of RNase H1-dependent ASO-mediated degradation of target RNA molecules has been determined. 65 There have been several clinical successes in the development of systemically administered RNAse H-active ASOs in nononcological settings. RNase Hactive ASOs targeting the disease-associated proteins ApoB100, APOCIII, and FXI have produced dosedependent pharmacology in humans, and, in several cases, near complete depletion of these liverderived proteins from plasma has been achieved. [66] [67] [68] [69] Importantly, Kynamro TM , the generation-2 ASO targeting ApoB100, was recently approved for the treatment of homozygous familial hypercholesterolemia, making it the first FDA-approved systemically delivered antisense drug. 67 Moreover, robust clinical efficacy of additional generation-2 ASOs including those targeting APOCIII in the triglyceride pathway and FXI, a regulator of thrombosis, has recently been reported in 2 separate seminal articles in The New England Journal of Medicine. 68, 69 As mentioned above, recent advances continue to further the pharmacologic properties, potency, and selectivity of ASO technology and have led to the discovery and clinical evaluation of next-generation cEt ASOs and GalNAc-conjugated ASOs that hold tremendous potential to modulate difficult-to-drug targets in many disease indications including cancer.
AGO2-Mediated RNA Cleavage and AGO2-Activating Agents
RNAi is another gene-silencing pathway that relies on the principle of antisense to produce its effects ( Figure 3) . 70, 71 However, it differs from the RNase H mechanism in several respects. RNAi is initiated by a double-stranded RNA molecule where the double strand is comprised of both a sense "passenger" RNA strand and a paired antisense or "guide" RNA strand. RNAi inhibitors (often called siRNAs) are usually formulated into nanoparticle delivery systems to overcome stability and delivery issues associated with this approach. 47 Once inside cells, the passenger RNA strand is degraded, and the antisense guide strand is loaded into a gene-silencing protein complex called the RISC complex. The antisense guide strand within the RISC complex is then targeted to a binding site on the cognate RNA target, where RNA cleavage is mediated by the RNA nuclease AGO2. 72 An important distinction between the RNAi mechanism and RNase H1-mediated inhibition of target RNAs is that AGO2-mediated cleavage takes place in the cytoplasm, whereas RNase H1-mediated cleavage induced by ASOs takes place principally in the nuclei of cells. 39 Several experimental RNAi (siRNA) therapeutic molecules are currently under clinical evaluation; however, no siRNA drugs have yet been approved as therapeutics.
A gene-silencing approach has recently been described that relies on stabilized single-stranded RNA drugs that work via the RISC-RNAi mechanism have been described. 73, 74 Moreover, this approach does not require any complex lipid formulations to overcome the stability and pharmacokinetic issues associated with double-stranded siRNAs and thus represents an exciting alternative to this therapeutic approach.
Since the discovery of RNAi, there have been approximately 30 different therapeutic siRNAs that have been evaluated in over 50 human clinical trials. The first studies were conducted in diseases where localized delivery was an option, for example, delivery to the eye for ocular diseases and to the lung for respiratory diseases. However, with the improvements in lipid nanoparticle technology, systemically delivered siRNA-based therapeutics became the norm. 49, 75, 76 As with therapeutic ASOs, clinical activity has been clearly demonstrated with siRNAs targeted to genes expressed in liver. Among the clearest examples of clinical activity for systemically administered lipid nanoparticle formulations of siRNA molecules is the targeted inhibition of the liver-expressed factor TTR, for TTRmediated amyloidosis by the TTR therapeutic siRNAs ALN-TTR01 and ALN-TTR02 (patisiran). In clinical studies dose-dependent and sustained lowering of TTR levels was achieved. Protein knockdown of up to 81% was observed, and inhibition was maintained at 50% for 28 days. Patisiran was shown to be superior to ALN-TTR01 in both potency and tolerability, with lower incidence of infusion-related reactions, the primary adverse reaction observed in the trials. 77 Based on these encouraging early results, phase 2 and 3 trials have being initiated to evaluate the safety, tolerability, and efficacy of patisiran in patients with transthyretin amyloidosis. The GalNAc-siRNA conjugation strategy for targeted delivery to hepatocytes has more recently been applied to TTR siRNAs, leading to the development of the GalNAc-siRNA TTR inhibitor, ALN-TTRSC (revusiran). In phase 1 clinical studies of revusiran, dose-dependent knockdown of up to 98% inhibition, serum TTR was achieved in healthy volunteers, and a phase 3 multicenter study of revusiran was initiated (ENDEAVOUR trial) to evaluate safety and efficacy of revusiran in patients with TTR-mediated familial amyloidotic cardiomyopathy. In October 2016, the development of revusiran was halted when an interim analysis of the ongoing ENDEAVOR trial revealed an imbalance of mortality in the revusiran arm compared to placebo.
Splice Modulating ASOs
Another ASO mechanism that is therapeutically attractive and is being evaluated more recently is ASOmediated modulation of RNA splicing. [78] [79] [80] Splicing reactions are sequence specific and require the concerted action of spliceosomes, and thus, oligonucleotides can be designed to bind to sequences required for splicing and prevent binding of necessary factors or physically prevent the required cleavage reactions. This can then result in inhibition of the production of the mature mRNA or, perhaps more importantly, a shift in exon incorporation in the mRNA yielding an mRNA that codes for a different version of the protein (see Figure 4 ). In the past several years substantial progress has been made with therapeutic antisense strategies that regulate alternative splicing. 81, 82 A variety of chemically modified antisense drugs have been shown to modulate splicing mechanisms in vitro and in vivo. However, for obvious reasons, to induce alternative splicing, antisense drugs that do not support the degradation of target RNAs must be employed. Uniformly modified ASOs containing 2ʹ-methoxy, MOE, peptide nucleic acid, morpholino, and locked nucleic acid modifications do not support RNase H activity have been most extensively studied. The antisense strategy to modulate pre-mRNA splicing has demonstrated robust preclinical therapeutic proof of concept in animal models of the neurodegenerative disease spinal muscular atrophy (SMA). 83 Systemically administered ASOs do not penetrate the central nervous system, and therefore they are not at risk to elicit central nervous system toxicities that are frequently observed with small-molecule drugs that often do cross the blood-brain barrier. However, splice-modulating ASOs administered directly into the central nervous system by intrathecal administration are pharmacologically active and have demonstrated proof of concept in several preclinical systems from rodents to nonhuman primates. 84 Recently, antisense drugs designed to alter splicing have entered human clinical trials and have shown signs of clinical activity in various disease settings, with the most compelling and clear demonstration of ASO-mediated splice modulation in man coming from the robust demonstration of clinical proof of mechanism with Isis SMN RX (nusinersen), where intrathecal administration of the splice-modulating ASO to children afflicted with SMA led to time-and dose-dependent increases in several muscle function parameters. 85, 86 Very recently, nusinersen, has unequivocally demonstrated that this approach is viable and can deliver significant clinical benefit in infants afflicted with SMA. 87 Importantly for SMA patients, an interim analysis of the phase 3 placebo-controlled clinical of nusinersen in this patient population demonstrated highly significant positive effects, and nusinersen (Spinraza) has now been approved by the Food and Drug Administration for the treatment of all patients with SMA.
With these encouraging results, there is great hope that central delivery of ASOs will represent an exciting strategy for the treatment of numerous severe neurodegenerative disorders. This strategy is potentially an attractive one in cancer as well, because it is well known that tumors often have misregulated splicing that could potentially be corrected by this approach. 88 
MicroRNA Modulators
MicroRNAs (also called miRNAs) are a family of short (19-25 nucleotides) non-protein-coding RNAs that play a role in the regulation of gene expression. The miRNAs hybridize to sequences on target RNAs through antisense base pairing, leading to the inhibition of mRNA translation and degradation of the target mRNA. 89, 90 A single or multiple mRNA molecules can be targeted by any given miRNA, and it is estimated that approximately 60% of human mRNAs are targeted and regulated to some degree by miRNAs. [91] [92] [93] The miRNA-regulated gene silencing is mediated through interaction of the miRNA/mRNA RNA duplex with the RNA-induced silencing complex (RISC) and by distinct mechanisms that result in either translational repression or mRNA degradation, depending on the degree of complementarity of the miRNA with target mRNA sequences. 94, 95 To date, over 2500 human miRNAs have been identified, and it is now recognized that complex networks of miRNAs regulate mammalian gene expression and many aspects of cellular biology. [96] [97] [98] Alterations in miRNA expression have been demonstrated to be associated with numerous human pathologies, including cancer, where miRNAs have been demonstrated to be involved in tumororigenesis and progression, behaving as tumor-promoting miRNAs (oncomiRNAs) or alternatively as tumor suppressor miRNAs ( Figure 5) . [99] [100] [101] [102] [103] [104] As a result, several antagonists of miRNAs or miRNA mimics have shown activity in preclinical cancer models, and several have advanced into clinical testing (see Table 2 ).
Therapeutic mRNA
The notion that mRNA itself could be employed therapeutically was proposed over 2 decades ago when it was demonstrated that intramuscular injection of an in vitro transcribed (IVT) mRNA or plasmid DNA into the skeletal muscles of mice resulted in the expression of the encoded protein locally in the muscle. 105 However, mRNA was not pursued further therapeutically, as it is less stable than DNA, and thus most efforts were concentrated on therapeutic technologies based plasma DNA and viral DNA. Nonetheless, since its discovery, mRNA has remained an area of strong scientific interest with great potential to treat various diseases.
Two distinct therapeutic approaches employing IVT mRNA have been pursued. The first involves the transfer if IVT into the patient's cells ex vivo, where these transfected cells (typically immune cells isolated from blood such as T cells or dendritic cells) are then adoptively transferred back to the patient. The second approach is the systemic delivery of the IVT mRNA in vivo to patients, and this is being developed for applications in oncology, infectious diseases, the treatment of allergies, and for various protein deficiency disorders.
There are several important distinctions between IVT mRNA-based therapeutic strategies and other nucleic acid-based therapies. First, IVT mRNA does not need to enter the nucleus of the target cell to be functional, as once it has reached the cytoplasm the mRNA can be translated directly into protein.
In contrast, with DNA therapeutics, functionality depends on delivery to the nucleus in order for the DNA first to be transcribed into RNA for the production of functional protein. However, therapeutic delivery to tissues and cells currently remains a challenge for DNA therapeutics and IVT mRNA-based approaches. Importantly, IVT mRNA-based therapeutics, unlike plasmid DNA and viral vectors, are generally thought not to integrate into the genome and therefore do not pose the risk of insertional mutagenesis, although this has not been unequivocally demonstrated.
In the field of cancer therapeutics specifically, the most advanced approaches to date have been therapeutic vaccination strategies, which have advanced to phase 2 clinical evaluation. 106 Protein replacement strategies have also been explored; however, these are currently at earlier stages of development. mRNA therapeutic strategies hold promise in the treatment of various diseases including cancer; however, the technical challenge of broad delivery of sufficient mRNA to target cell populations has relied to date on complex lipid nanoparticle formulations and is as yet unresolved.
Therapeutic Advances With RNA-Based Therapeutics in Oncology
Clinical Experience With AGO2 Activating Agents in Cancer Principally due to the tissue distribution of siRNA inhibitors, most of these agents currently in advanced clinical trials are being employed for targets expressed in normal liver. However, several siRNA inhibitors are also currently being evaluated in cancer clinical trials, and in all these trials the siRNA molecules have been formulated into various types of nanoparticles including lipid nanoparticles or liposomes. [47] [48] [49] [50] [51] [52] Most of these remain at early stages of development, and the data are not yet mature enough to determine their clinical potential. However, evidence of siRNA-mediated target inhibition on systemic delivery for a human solid tumor (melanoma) has been demonstrated, first in a clinical trial with CALAA-01, an siRNA-targeting ribonuclease reductase subunit 2 that is complexed with a cyclodextrin polymer coated with polyethylene glycol and decorated with human transferrin protein on the surface of the particle. The transferrin moiety of the molecule is designed to increase the targeting to tumor cells that overexpress the transferrin receptor on their surface. Preliminary results from a phase 1 trial suggest that the siRNA was effectively delivered to tumor tissue as demonstrated by a reduction in ribonucleotide reductase mRNA and the generation of RNA cleavage products in tumor biopsy, corresponding to siRNA target site on the mRNA. 52 In this study however, dose-limiting toxicity was observed in several patients, and the trial was terminated.
Evidence suggestive of disease-modifying activity in cancer has been achieved with Atu027, a siRNA targeting protein kinase N3 that is also formulated into a cationic lipid nanoparticle. In a phase 1 study in patients with solid tumors, Atu027 was shown to be well tolerated and caused disease stabilization in 52% of patients including 1 patient who experienced complete regression of pulmonary lesions. 107 More recently, a post hoc analysis of data from a phase 1b/2a trial of Atu027 in combination with standard gemcitabine treatment in patients with advanced or metastatic pancreatic adenocarcinoma demonstrated a statistically significant increase in progression-free survival in the Atu027 arm. 108 The siRNA siG12D, which is selective for mutant KRAS (KRASG12D mutation), is encapsulated in a biodegradable polymer Local Drug Eluter (LODER) for controlled and prolonged delivery. 109 A phase 1 trial was conducted in patients with locally advanced adenocarcinoma of the pancreas to assess efficacy and local distribution after intratumoral injection of siG12D-LODER by an endoscopic ultrasound needle. This drug has now advanced into a phase 2 study to assess its efficacy in combination with gemcitabine or folfirinox chemotherapy in patients with unresectable locally advanced pancreatic cancer. 110 TKM-PLK1 (TKM-080301), is a lipid nanoparticleencapsulated siRNA targeting the polo kinase-1 RNA. A phase 1/2 study demonstrated that the drug was well tolerated in patients with hepatocellular carcinoma or neuroendocrine tumors and adrenocortical carcinoma, and Arbutus Inc, the company developing the drug, reported top-line results demonstrating that 51% of treated patients had disease stabilization, and 22% of patients had achieved a partial response.
The myc oncogene is involved in the progression of many human tumors and therefore has long been thought to be an important cancer target. 111 DCR-MYC is a lipid nanoparticle-encapsulated myc siRNA that has demonstrated interesting early activity in patients with pancreatic neuroendocrine tumors. In the initial phase 1 study of DCR-MYC, 2 out of 3 patients with pancreatic neuroendocrine tumors had tumor mass reductions, and 1 patient achieved a partial remission (34% tumor size reduction). 112 Based on these data an expansion study of DCR-MYC in up to 20 additional patients with pancreatic neuroendocrine tumors has been initiated.
siRNA-based therapeutics have great potential as cancer therapeutics; however, many challenges remain, including rapid degradation, poor cellular uptake, and off-target effects. Improvements in chemical modifications and nanocarriers have the potential to make the translational process faster and more effective in the near future and to open the door to development of highly effective and safe therapeutics for clinical applications.
Clinical Experience With miRNA Modulators
As mentioned above, miRNAs have been implicated in the pathogenesis of several diseases. Not surprisingly then, miRNA-targeting therapies are an area of intense interest to pharmaceutical companies, and several compounds have advanced to clinical development for a variety of indications.
The strongest clinical proof of concept for mirtargeting agents to date has come from the evaluation of the mir-122 antagamir miravirsen in patients with hepatitis C. miR-122 is a liver-specific miRNA that can modulate HCV replication. 113 Consistent with this, miravirsen inhibited HCV replication and was advanced into clinical trials for the treatment of HCV infection. In phase 1 studies in healthy volunteers, miravirsen was well tolerated and displayed no dose-limiting toxicities. Impressively, in a phase 2 study in patients with chronic HCV infections, treatment with miravirsen resulted in a mean 2-to 3-log decrease in serum HCV RNA, and HCV RNA was below detectable levels in 4 of the 9 treated patients. 114, 115 These impressive data were the first to demonstrate that anti-miR oligonucleotide drugs can achieve clinically meaningful efficacy. An even more potent mir-122 drug (RG-101), which contains a GalNAc targeting moiety to increase targeting to the liver, has entered clinical development. However, in June 2016 RG-101 was put on clinical hold by the FDA due to a case of severe jaundice in 1 patient.
Several miRNA modulators for the treatment of cancer have also advanced into clinical testing, but most are currently still at early stages and, as with siRNA inhibitors for cancer, the data are not yet mature enough to gauge the clinical potential of this class of drugs. The miR-34 family of miRNAs was first implicated in cancer when the coding locus was linked with genomic regions that are frequently deleted in several human tumors. 103 Since then, several studies have demonstrated that miR-34 is an important regulator S53 of multiple oncogenes involved in cell cycle control, cell proliferation, apoptosis, and metastasis and, consistent with a function role in cancer, its expression is deregulated in many cancer cells. 116 These data suggested that miR-34 mimics might be an attractive therapeutic strategy to restore the normal regulation of a range of cell death and survival genes in cancer cells. Consistent with this hypothesis, the mir-34 mimic MRX34, a lipid-formulated miR-34 mimic, has demonstrated efficacy in several preclinical models of cancer.
117 MRX34 is the first miRNA-targeted agent in cancer clinical trials and is currently in phase 1 clinical studies in patients with various solid tumors and hematologic cancers. 118 Other miRNA therapeutics nearing clinical development include the mir-mimic to Let-7. Let-7 was shown to induce growth arrest in multiple cancer cell lines, especially those with KRAS mutations, and to suppress tumor growth in models of human lung cancer. 119, 120 These data suggest that the delivery of let-7 miRNA into tumors may have therapeutic benefit in patients with cancer with KRAS mutations that are otherwise untreatable. Let-7 drugs are currently in preclinical development.
miRNAs encoded by the mir-15/16 cluster have been demonstrated to act as tumor suppressors, and downregulation of both of these miRs has been found in multiple types of human tumors, particularly in mesothelioma. [121] [122] [123] A therapeutic approach to restoring mir-15/mir-16 expression termed targomirs is an approach comprised of a combination of mir-15/mir-16 mimetic drugs encapsulated in a bacterial cellderived system, coated with an epidermal growth factor receptor-targeting antibody. 124 Infusions of targomirs were associated with a steep rise in inflammatory cytokines and elevations in liver enzymes; however, these were transient, and several patients reported improved quality of life while on treatment. 123, 124 microRNA-modulating drugs are an exciting class of RNA therapeutics as individual miRNAs regulate the expression of multiple important biological pathways. It will be exciting to see how this new class of drugs evolves as cancer therapeutics.
Clinical Experience With mRNA Targeting Single-Stranded ASOs in Oncology
Therapeutic ASO Advances in Oncology As discussed above, genomic insights into cancer now allow the stratification of tumors based on molecular profiles rather than on tissues of origin. Lung cancer, for example, can be divided into more than 10 distinct subtypes, each with unique mutation and gene expression profiles. Therefore, cancer represents a tremendous opportunity for gene-selective approaches such as antisense technology that can potentially target previously identified as well as newly discovered undruggable pathways and, importantly, then be employed in the patient population it is most likely to benefit. Generation-2.0 ASOs have historically shown less potent effects in extrahepatic and extrarenal tissues that accumulate lower concentrations of these drugs, including, for example, skeletal muscle and tumors. As a result, the clinical experience with this generation-2.0 ASO in the treatment of cancer compared to other disease areas has been limited and is still limited. Despite this, early proof-of-concept studies and encouraging phase 2 efficacy data demonstrate that with higher doses, generation-2.0 ASOs targeted to either survivin (LY2181308) or clusterin (OGX-011, custirsen) resulted in the inhibition of their target RNA and protein levels in tumor cells of cancer patients. 125, 126 In the case of OGX-011, encouraging signs of clinical efficacy were also observed where increased time to progression-free survival was demonstrated in a phase 2 prostate cancer trial. 127, 128 Unfortunately, however, a more recent evaluation of the top-line results from the phase 3 SYNERGY Trial of OGX-011 in advanced prostate cancer did not meet its primary end point. However, OGX-011 is still currently being evaluated in the phase 3 study (ENSPIRIT) in advanced non-small-cell lung cancer in combination with docetaxel.
Heat shock protein 27 (Hsp27) is a chaperone protein that regulates cell survival via androgen receptor and other signaling pathways. 129, 130 Apatorsen (OGX-427) is a 2'-MOE-modified antisense oligonucleotide that inhibits Hsp27 expression and has been evaluated in patients with advanced cancers with a focus on prostate cancer. In a phase 1 study, decreases in tumor markers and declines in circulating tumor cells were observed, with a prostate-specific antigen decline >50% occurring in 10% of patients with castration-resistant prostate cancer, and 29/39 assessable patients (74%) had reductions from ࣙ5 to <5 circulating tumor cells per 7.5 mL from baselone to posttreatment, and 12 patients had stable measurable disease as best response. 131 Taken together, these data suggest that generation-2.0 ASOs have activity in patients with cancer but that further improvements in ASO potency may ultimately represent the best means to effectively target difficult to drug diverse driver pathways in cancer that have been so elusive to date. significantly increased affinity for their target RNA and thus have greatly increased potency in vitro and in vivo compared to generation 2.0 ASOs. 45, 46 Importantly, generation 2.5 cEt ASOs can be employed both in vitro and in vivo without the need for any complex lipid delivery or nanoparticle systems. The incorporation of generation 2.5 chemistry into ASOs also significantly increases the range of tissue in which potent antisense pharmacology can be achieved to include previously difficult to target tissues such as tumors and skeletal muscle. 132 Isis STAT3 Rx (AZD9150) and AR Rx (AZD5312) The first generation 2.5 ASO drug to enter human clinical trials is Isis-STAT3 RX , which targets the RNA coding for the protein STAT3. STAT3 is a member of the signal transduction and activator of transcription (STAT) family of latent cytoplasmic transcription factors and is an attractive cancer target implicated in the regulation of expression of many genes involved in diverse aspects of tumor biology. 133 As a transcription factor, STAT3 has for decades been recalcitrant to inhibition with small-molecule inhibitors. Moreover, because STAT3 is 1 member of a family of 6 closely related proteins, STAT3 represents a particularly attractive antisense therapeutic target because of the selectivity of the ASO approach. Isis-STAT3 Rx now licensed by AstraZeneca, and called AZD9150, and has demonstrated good safety and exciting early signs of clinical efficacy, including single-agent robust antitumor activity in highly refractory patients with various types of lymphoma and hepatocellular cancer. 134, 135 Based on these data STAT3 RX /AZD9150 has been advanced into multiple phase 2 clinical trials in various tumor types (see Figure 6 ).
The second generation 2.5 ASO to enter human cancer trials is the androgen receptor inhibitor Isis AR RX (AZD5312). AZD5312 is an exciting molecule as it targets both the full-length androgen receptor RNA as well as several splice variants of AR that are associated with resistance to commonly used antiandrogen therapies in prostate cancer.
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Conclusions, Remaining Challenges, and Future Directions
The development of RNA therapeutics has amounted to the creation of a new pharmacology. There is currently great promise that these approaches will become one of the next major classes of therapeutics. However, just as it has taken great perseverance to advance these modalities to where they are today, it will require continued dedication to fulfill the potential of this technology to treat various human diseases.
As cancer therapeutics, ASOs and siRNAs have demonstrated early proof of mechanism in humans and early clinical efficacy and provide great encouragement that these technologies will ultimately be successfully applied to target traditionally undruggable cancer S55 drivers and thereby significantly impact the treatment of human cancer. A particularly promising advance toward this is the advent of the next-generation ASO chemistry (generation 2.5 cEt-containing ASOs), which has dramatically increased potency and activity in more difficult to target extrahepatic tissues including tumors. A significant advantage of cEt-containing ASOs over siRNAs and other approaches is that they do not require lipid or nanoparticle delivery systems in vitro or in vivo, thus overcoming 1 of the principal liabilities of other oligonucleotide approaches, namely the safety issues associated with the currently available nanoparticle delivery systems.
As promising as the early clinical activity has been for various RNA therapeutics, several key challenges remain. The ADME properties of either unformulated ASOs and miRNA therapeutics or nanoparticleencapsulated siRNAs are limiting. On systemic delivery, these agents distribute broadly to most tissues, although the liver and kidney are the main target organs, 29 and tumors accumulate less. Uptake into tumor cells themselves and release of drug from endosomal compartments into the respective productive compartments for activity (the nucleus for ASOs and miRNA drugs and the cytoplasm for siRNAs) also limit the maximal activity of these agents. The targeted delivery and uptake of RNA therapeutics into hepatocytes through GalNAc conjugation have overcome many ADME challenges for therapeutic targets expressed in the liver. Thus, it is anticipated that the identification of ligand-receptor systems enabling the targeted delivery of RNA therapeutics to various tumor types would similarly be game-changing for these technologies in cancer. The safety profile of RNA therapeutics, although generally acceptable for cancer treatment, will certainly be enhanced by advances in nanoparticle delivery modalities for siRNAs and by the increased potency of ASOs with next-generation chemistries and with targeted delivery approaches and will thus translate into increased therapeutic margins. 138 It is envisioned that with continued dedication to these technologies, RNA therapeutics will be a key component of future personalized medicine approaches to the treatment of cancer, where sequencing of the genes from a patient's tumor would identify key driver mutations or drug resistance mutations that could then be selectively targeted with RNA therapeutics specific for that alteration and that, ideally, these could be selectively delivered to the tumor cells of interest with a targeted delivery moiety. In this future, the drugs of choice would be different for individual cancer patients dependent on the constellation of aberrations identified and could also include inhibitors of pathways anticipated to mediate resistance to treatments and thus greatly improve the outcome for patients suffering from cancer.
